Financial News · Live Terminal

Page 63 of 307

Choice Equity Downgrades Tilaknagar Industries to Add from Buy; Price Target is INR520

CLSA Upgrades OBIC to Buy from Accumulate; Price Target is 6,200 Yen

OBIC (TYO:4684) has an average rating of overweight and mean price target of 5,242.31 yen, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

TYO:4684

Research25d ago

Maybank Securities Starts UI Boustead REIT at Buy with SG$1.03

SGX:UIBU

Research25d ago

UOB Kay Hian Upgrades Meituan to Hold from Sell; Price Target is HK$76

Meituan (HKG:3690) has an average rating of overweight and mean price target of HK$109.46, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

HKG:3690

Research25d ago

Raymond James Upgrades Atlas Energy Solutions to Outperform From Market Perform, PT is $25

Atlas Energy Solutions (AESI) has an average rating of hold and mean price target of $19.64, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$AESI

Research25d ago

Goldman Sachs Initiates Mobia Medical at Buy With $31 Price Target

$MOBI

Research25d ago

JPMorgan Initiates Mobia Medical at Overweight With $15 Price Target

$MOBI

Research25d ago

BNP Paribas Initiates Octave Intelligence at Outperform With $25 Price Target

Octave Intelligence (OCTV) has an average rating of overweight and mean price target of $23.88, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$OCTV

Research25d ago

JPMorgan Initiates Odyssey Therapeutics at Overweight With $26 Price Target

$ODTX

Research25d ago

BNP Paribas Initiates CoreWeave at Outperform With $192 Price Target

CoreWeave (CRWV) has an average rating of overweight and mean price target of $140.15, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$CRWV

Research25d ago

BNP Paribas Initiates Nebius Group at Neutral With $255 Price Target

Nebius Group N.V (NBIS) has an average rating of overweight and mean price target of $248.86, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$NBIS

Research25d ago

Cantor Fitzgerald Initiates Rare Earths Americas at Speculative Buy With $34 Price Target

$REA

Research25d ago

Goldman Sachs Downgrades Intuit to Sell From Neutral, Adjusts Price Target to $276 From $519

Intuit (INTU) has an average rating of buy and mean price target of $491.76, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$INTU

Research25d ago

Mizuho Downgrades Consolidated Edison to Neutral From Outperform, Adjusts PT to $105 From $118

Consolidated Edison (ED) has an average rating of hold and mean price target of $110.40, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$ED

Research25d ago

UBS Downgrades Sherwin-Williams to Neutral From Buy, Adjusts Price Target to $330 From $385

Sherwin-Williams (SHW) has an average rating of overweight and mean price target of $382.17, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$SHW

Research25d ago

Arete Upgrades Meta Platforms to Buy From Neutral, Adjusts Price Target to $735 From $614

Meta Platforms (META) has an average rating of buy and mean price target of $820.33, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$META

Research25d ago

Research Alert: CFRA Maintains Hold Rating On Shares Of Dexcom Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month price target to $83 (from $67), 32x our 2026 EPS estimate, near DXCM's one-year historical forward average of 32.9x and well below its longer-term historical averages to reflect increased competition within the continuous glucose monitoring space, in our view. We lift our 2026 EPS estimate by $0.01 to $2.59 and raise our 2027 estimate by $0.02 to $3.07. We think the addressable market for DXCM is large and far from saturated, but a slower sales growth rate is a concern, which we attribute to market share losses and slow progress in gaining additional insurance coverage. We see the upcoming CONNECT study (for type-2 non-insulin patients) readout as a potentially significant near-term catalyst which may drive enhanced insurance coverage. DXCM sees CMS coverage for all individuals with diabetes by mid-2027, which it believes will increase its addressable U.S. market for type-2 non-insulin intensive diabetes by around 80% to 27M people.

$DXCM

Research25d ago

Research Alert: CFRA Reiterates Sell Rating On Science Applications International Corporation

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We increase our target by $20 to $100 on a P/E of 9.2x our FY 28 (Jan.) EPS view, below historical (13.6x) and peers (12.6x), reflecting lower revenue expectations. We raise our FY 27 EPS estimate to $10.13 from $9.50 and FY 28's to $10.90 from $10.65. Management raised FY 27 guidance across key profitability metrics while maintaining revenue expectations, reflecting confidence in margin sustainability but continued caution on top-line growth. Adj. EBITDA guidance increased to $720M-$730M from $705M-$715M, with margin guidance raised to 10.1%-10.3% from 9.9%-10.1%. Adj. diluted EPS guidance was lifted to $9.90-$10.10 from $9.50-$9.70. However, revenue guidance remained unchanged, implying organic declines of 2%-4% for FY 27, suggesting a cautious outlook on the procurement environment despite the quarter's stabilization.Before becoming more constructive, we need to see sustained strong bookings drive top-line growth, proving SAIC can execute its portfolio pivot and offset significant recompete headwinds.

$SAIC

Research25d ago

Research Alert: Hpe Q2: Massive Beats And Guidance Increases As Ai Tailwinds Strengthen

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:HPE reported Q2 FY 26 (Apr-Q) results that blew away consensus expectations, with non-GAAP EPS of $0.79 (+108% Y/Y) beating expectations for $0.53 and revenue of $10.68B (+40% Y/Y) coming in ahead of the Street's $9.76B view. Non-GAAP gross margin expanded 750 bps Y/Y while operating margin of 13.3% was up 530 bps. Results reflect growing AI demand and the strength of HPE's networking portfolio, with Networking sales surging 148% Y/Y (driven by the Juniper acquisition) and Cloud & AI segment revenue growing 23% Y/Y to $7.7B. FY 26 guidance was raised materially, with HPE's revenue midpoint now at $44.9B (consensus $40.84B), non-GAAP EPS lifted to a midpoint of $3.40 from a prior $2.40 view (consensus $2.42), and FCF guidance upped to at least $3.5B from at least $2.0B. Management also provided initial FY 27 sales growth expectations at about 10%, placing FY 27 sales around $49.4B (14% above consensus) in a confident move that reflects improving visibility and strengthening AI tailwinds.

$HPE

Research25d ago

Research Alert: CFRA Lowers Opinion On Shares Of American Airlines Group Inc. To Sell From Hold

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our opinion on AAL to Sell from Hold, reduce our price target by $1 to $12, and cut our 2026 EPS to -$0.07 from $0.48 and 2027's to $1.72 from $1.93, primarily reflecting fuel costs. Our target reflects 7x 2027 EPS (from 6.5x), with the modest multiple expansion reflecting strong underlying industry travel trends despite higher airfare, partially offsetting our estimate reductions. In our view, AAL is most exposed to fuel costs, given a higher unit cost profile and lagging unit revenue performance versus peers. While Q1 unit revenue rose 6.5% Y/Y, the spread between AAL's unit revenue and unit costs (+5.2% Y/Y) is tighter than peers and could result in operating losses more quickly. This profile justifies our discounted multiple versus peers in the high-single-digit range. AAL is also leaning into summer capacity, potentially driving higher fuel consumption at elevated prices. We see limited margin for error if fuel headwinds persist. A key upside risk is oil prices easing faster than expected.

$AAL

Showing 1241-1260 of 6129